Press release content from Globe Newswire. The AP news staff was not involved in its creation. Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million RP Management, LLCApril 8, 2021 GMT Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMOâ...